Literature DB >> 10362109

Amphiregulin acts as an autocrine growth factor in two human polarizing colon cancer lines that exhibit domain selective EGF receptor mitogenesis.

L Damstrup1, S K Kuwada, P J Dempsey, C L Brown, C J Hawkey, H S Poulsen, H S Wiley, R J Coffey.   

Abstract

Colonic enterocytes, like many epithelial cells in vivo, are polarized with functionally distinct apical and basolateral membrane domains. The aims of this study were to characterize the endogenous epidermal growth factor (EGF)-like ligands expressed in two polarizing colon cancer cell lines, HCA-7 Colony 29 (HCA-7) and Caco-2, and to examine the effects of cell polarity on EGF receptor-mediated mitogenesis. HCA-7 and Caco-2 cells were grown on plastic, or as a polarized monolayer on Transwell filters. Cell proliferation was measured by 3H-thymidine incorporation and EGF receptor (EGFR) binding was assessed by Scatchard analysis. EGFR ligand expression was determined by Northern blot analysis, reverse transcription polymerase chain reaction, metabolic labelling and confocal microscopy. We found that amphiregulin (AR) was the most abundant EGFR ligand expressed in HCA-7 and Caco-2 cells. AR was localized to the basolateral surface and detected in basolateral-conditioned medium. Basolateral administration of neutralizing AR antibodies significantly reduced basal DNA replication. A single class of high-affinity EGFRs was detected in the basolateral compartment, whereas the apical compartment of polarized cells, and cells cultured on plastic, displayed two classes of receptor affinity. Basolateral administration of transforming growth factor alpha (TGF-alpha) or an EGFR neutralizing antibody also resulted in a dose-dependent stimulation or attenuation, respectively, of DNA replication. However, no mitogenic response was observed when these agents were added to the apical compartment or to confluent cells cultured on plastic. We conclude that amphiregulin acts as an autocrine growth factor in HCA-7 and Caco-2 cells, and EGFR ligand-induced proliferation is influenced by cellular polarity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10362109      PMCID: PMC2363033          DOI: 10.1038/sj.bjc.6690456

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  38 in total

1.  Amphiregulin messenger RNA is elevated in psoriatic epidermis and gastrointestinal carcinomas.

Authors:  P W Cook; M R Pittelkow; W W Keeble; R Graves-Deal; R J Coffey; G D Shipley
Journal:  Cancer Res       Date:  1992-06-01       Impact factor: 12.701

2.  Epidermal growth factor receptor binding is not a simple one-step process.

Authors:  K H Mayo; M Nunez; C Burke; C Starbuck; D Lauffenburger; C R Savage
Journal:  J Biol Chem       Date:  1989-10-25       Impact factor: 5.157

3.  p1B15: a cDNA clone of the rat mRNA encoding cyclophilin.

Authors:  P E Danielson; S Forss-Petter; M A Brow; L Calavetta; J Douglass; R J Milner; J G Sutcliffe
Journal:  DNA       Date:  1988-05

4.  Human enterocyte (Caco-2) migration is modulated in vitro by extracellular matrix composition and epidermal growth factor.

Authors:  M D Basson; I M Modlin; J A Madri
Journal:  J Clin Invest       Date:  1992-07       Impact factor: 14.808

5.  Distinctive patterns of hyperplasia in transgenic mice with mouse mammary tumor virus transforming growth factor-alpha. Characterization of mammary gland and skin proliferations.

Authors:  S A Halter; P Dempsey; Y Matsui; M K Stokes; R Graves-Deal; B L Hogan; R J Coffey
Journal:  Am J Pathol       Date:  1992-05       Impact factor: 4.307

6.  Microtubular organization and its involvement in the biogenetic pathways of plasma membrane proteins in Caco-2 intestinal epithelial cells.

Authors:  T Gilbert; A Le Bivic; A Quaroni; E Rodriguez-Boulan
Journal:  J Cell Biol       Date:  1991-04       Impact factor: 10.539

7.  Autocrine action of amphiregulin in a colon carcinoma cell line and immunocytochemical localization of amphiregulin in human colon.

Authors:  G R Johnson; T Saeki; A W Gordon; M Shoyab; D S Salomon; K Stromberg
Journal:  J Cell Biol       Date:  1992-08       Impact factor: 10.539

8.  High-affinity epidermal growth factor binding is specifically reduced by a monoclonal antibody, and appears necessary for early responses.

Authors:  F Bellot; W Moolenaar; R Kris; B Mirakhur; I Verlaan; A Ullrich; J Schlessinger; S Felder
Journal:  J Cell Biol       Date:  1990-02       Impact factor: 10.539

9.  Signal transduction by epidermal growth factor occurs through the subclass of high affinity receptors.

Authors:  L H Defize; J Boonstra; J Meisenhelder; W Kruijer; L G Tertoolen; B C Tilly; T Hunter; P M van Bergen en Henegouwen; W H Moolenaar; S W de Laat
Journal:  J Cell Biol       Date:  1989-11       Impact factor: 10.539

10.  Receptor-mediated vectorial transcytosis of epidermal growth factor by Madin-Darby canine kidney cells.

Authors:  E Maratos-Flier; C Y Kao; E M Verdin; G L King
Journal:  J Cell Biol       Date:  1987-10       Impact factor: 10.539

View more
  20 in total

Review 1.  Multiple personalities of neuregulin gene family members.

Authors:  D A Talmage; L W Role
Journal:  J Comp Neurol       Date:  2004-04-26       Impact factor: 3.215

2.  Ret heterozygous mice have enhanced intestinal adaptation after massive small bowel resection.

Authors:  Meredith C Hitch; Jennifer A Leinicke; Derek Wakeman; Jun Guo; Chris R Erwin; Kathryn J Rowland; Ellen C Merrick; Robert O Heuckeroth; Brad W Warner
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-03-15       Impact factor: 4.052

3.  Identification of a novel mono-leucine basolateral sorting motif within the cytoplasmic domain of amphiregulin.

Authors:  Jonathan D Gephart; Bhuminder Singh; James N Higginbotham; Jeffrey L Franklin; Alfonso Gonzalez; Heike Fölsch; Robert J Coffey
Journal:  Traffic       Date:  2011-10-13       Impact factor: 6.215

4.  Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor.

Authors:  Klaus Koefoed; Lucilla Steinaa; Josefine Nielsen Søderberg; Ida Kjær; Helle Jane Jacobsen; Per-Johan Meijer; John Sørensen Haurum; Allan Jensen; Michael Kragh; Peter Sejer Andersen; Mikkel Wandahl Pedersen
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

5.  Oncogenic KRAS desensitizes colorectal tumor cells to epidermal growth factor receptor inhibition and activation.

Authors:  Winan J van Houdt; Frederik J H Hoogwater; Menno T de Bruijn; Benjamin L Emmink; Maarten W Nijkamp; Danielle A E Raats; Petra van der Groep; Paul van Diest; Inne H M Borel Rinkes; Onno Kranenburg
Journal:  Neoplasia       Date:  2010-06       Impact factor: 5.715

6.  In vitro combined treatment with cetuximab and trastuzumab inhibits growth of colon cancer cells.

Authors:  T Luca; V Barresi; G Privitera; N Musso; M Caruso; D F Condorelli; S Castorina
Journal:  Cell Prolif       Date:  2014-08-08       Impact factor: 6.831

Review 7.  Trafficking of epidermal growth factor receptor ligands in polarized epithelial cells.

Authors:  Bhuminder Singh; Robert J Coffey
Journal:  Annu Rev Physiol       Date:  2013-11-08       Impact factor: 19.318

8.  Bile acid alone, or in combination with acid, induces CDX2 expression through activation of the epidermal growth factor receptor (EGFR).

Authors:  Nelly E Avissar; Liana Toia; Yingchuan Hu; Thomas J Watson; Carolyn Jones; Daniel P Raymond; Alexi Matousek; Jeffrey H Peters
Journal:  J Gastrointest Surg       Date:  2008-10-15       Impact factor: 3.452

9.  The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies.

Authors:  Cyril Sobolewski; Claudia Cerella; Mario Dicato; Lina Ghibelli; Marc Diederich
Journal:  Int J Cell Biol       Date:  2010-03-17

10.  Proneoplastic effects of PGE2 mediated by EP4 receptor in colorectal cancer.

Authors:  Glen A Doherty; Sinead M Byrne; Eamonn S Molloy; Vikrum Malhotra; Sandra C Austin; Elaine W Kay; Frank E Murray; Desmond J Fitzgerald
Journal:  BMC Cancer       Date:  2009-06-26       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.